Titan Spine has seen new data published that favourably compares cellular response to its own surface technology to that provoked by exposure to PEEK, one of the more widely used materials in spinal implants these days.
Titan Spine describes itself as a surface technology company, focused as it is on developing innovative spinal interbody fusion implants. The company’s full line of Endoskeleton® devices features its proprietary implant surface technology, consisting of a unique combination of roughened topographies at the macro, micro, and cellular levels. These features, it says are designed to provide an optimal host-bone response and actively participate in the fusion process by “promoting the upregulation of osteogenic and angiogenic factors necessary for bone growth.” That means hitting the sweet spot of encouraging natural production of bone morphogenetic proteins (BMPs), downregulating inflammatory factors, and thereby creating the potential for a faster and more robust fusion.
Data from a newly published (Spine, March 15) study compares its proprietary surface technology to polyetheretherketone (PEEK). The data demonstrate that Titan’s line of Endoskeleton® Interbody Devices promote osteoblastic differentiation and enhanced bone-forming environment compared to devices made from PEEK. Specifically, the data show that fibrous tissue formation around PEEK implants may be due to the creation of an inflammatory environment.
Barbara Boyan, Ph.D., Dean of the School of Engineering at Virginia Commonwealth University, and lead author of the study, said, “These results indicate that Titan’s surface reduces production of inflammatory mediators and increases production of anti-inflammatory mediators compared to PEEK, thus creating an enhanced environment for bone growth and fusion. Fibrous tissue formation around PEEK spinal implants is due to several factors including increased inflammatory cytokines and decreased cell viability. These data add to the growing body of medical knowledge supporting the use of titanium implants featuring a complex roughened topography at the macro-micro-nano (MMN) levels that induce healing on the cellular level where it is critical for early bone formation.”
Chief Executive Officer of Titan Spine, former surgeon Peter Ullrich, MD, commented; “This study is yet another example in a rapidly growing body of evidence that PEEK is a poor material for promoting bone growth. Until recently, PEEK was thought to be inert at best. We now understand that is not the case. Dr. Boyan’s research demonstrates that PEEK is actually inhibitory to bone forming cells, called osteoblasts, through the upregulation of pro-inflammatory markers. This leads to fibrous tissue formation, rather than bone formation, as the body attempts to protect itself from PEEK through encapsulation. We were pleased when the IMAST program committee recognized the importance of these data by granting it with the Whitecloud Award. Titan will continue to be at the forefront of scientifically engineering superior interbody fusion devices and promoting titanium as the preferred material for bone growth and fusion.”
Source: Business Wire